APO RESEARCH · REPORT
Oncology Drugs
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
Product & engineering
Understand the product.
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
Selected research
Industry Research
Oncology Drugs Industry Research Report 2026
Market perspective
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Read the full market overview
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.
Report Scope
This report quantifies the global Oncology Drugs market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oncology Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oncology Drugs Market by Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Oncology Drugs Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Oncology Drugs Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
Oncology Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncology Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Others
Applications
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory or Lung Cancer
- Others
Companies covered
- Roche
- Celgene
- Novartis
- Bristol-Myers Squibb
- Johnson & Johnson
- Merck & Co.
- AstraZeneca
- Pfizer
- Amgen
- Eli Lilly
- AbbVie
- Takeda
- Astellas
- Ipsen
- Sanofi
- Bayer
- Biogen Idec
- Teva
- Otsuka
- Eisai
- Merck KGaA
- Gilead Sciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oncology Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Chemotherapy
- 2.2.3 Targeted Therapy
- 2.2.4 Immunotherapy (Biologic Therapy)
- 2.2.5 Hormonal Therapy
- 2.2.6 Others
- 2.3 Oncology Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Blood Cancer
- 2.3.3 Breast Cancer
- 2.3.4 Gastrointestinal Cancer
- 2.3.5 Prostate Cancer
- 2.3.6 Respiratory or Lung Cancer
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Oncology Drugs Breakdown Data by Type
- 3.1 Global Oncology Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Oncology Drugs Forecasted Market Size by Type (2027-2032)
4 Oncology Drugs Breakdown Data by Application
- 4.1 Global Oncology Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Oncology Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oncology Drugs Market Perspective (2021-2032)
- 5.2 Global Oncology Drugs Growth Trends by Region
- 5.2.1 Global Oncology Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oncology Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Oncology Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Oncology Drugs Market Dynamics
- 5.3.1 Oncology Drugs Industry Trends
- 5.3.2 Oncology Drugs Market Drivers
- 5.3.3 Oncology Drugs Market Challenges
- 5.3.4 Oncology Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oncology Drugs Players by Revenue
- 6.1.1 Global Top Oncology Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Oncology Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Oncology Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oncology Drugs Head Office and Area Served
- 6.4 Global Oncology Drugs Players, Product Type & Application
- 6.5 Global Oncology Drugs Manufacturers Established Date
- 6.6 Global Oncology Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oncology Drugs Market Size (2021-2032)
- 7.2 North America Oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oncology Drugs Market Size by Country (2021-2026)
- 7.4 North America Oncology Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oncology Drugs Market Size (2021-2032)
- 8.2 Europe Oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oncology Drugs Market Size by Country (2021-2026)
- 8.4 Europe Oncology Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oncology Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oncology Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oncology Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oncology Drugs Market Size (2021-2032)
- 10.2 South America Oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oncology Drugs Market Size by Country (2021-2026)
- 10.4 South America Oncology Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oncology Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oncology Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oncology Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in Oncology Drugs Business (2021-2026)
- 12.1.4 Roche Oncology Drugs Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Celgene
- 12.2.1 Celgene Company Information
- 12.2.2 Celgene Business Overview
- 12.2.3 Celgene Revenue in Oncology Drugs Business (2021-2026)
- 12.2.4 Celgene Oncology Drugs Product Portfolio
- 12.2.5 Celgene Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Oncology Drugs Business (2021-2026)
- 12.3.4 Novartis Oncology Drugs Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2021-2026)
- 12.4.4 Bristol-Myers Squibb Oncology Drugs Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 Johnson & Johnson
- 12.5.1 Johnson & Johnson Company Information
- 12.5.2 Johnson & Johnson Business Overview
- 12.5.3 Johnson & Johnson Revenue in Oncology Drugs Business (2021-2026)
- 12.5.4 Johnson & Johnson Oncology Drugs Product Portfolio
- 12.5.5 Johnson & Johnson Recent Developments
- 12.6 Merck & Co.
- 12.6.1 Merck & Co. Company Information
- 12.6.2 Merck & Co. Business Overview
- 12.6.3 Merck & Co. Revenue in Oncology Drugs Business (2021-2026)
- 12.6.4 Merck & Co. Oncology Drugs Product Portfolio
- 12.6.5 Merck & Co. Recent Developments
- 12.7 AstraZeneca
- 12.7.1 AstraZeneca Company Information
- 12.7.2 AstraZeneca Business Overview
- 12.7.3 AstraZeneca Revenue in Oncology Drugs Business (2021-2026)
- 12.7.4 AstraZeneca Oncology Drugs Product Portfolio
- 12.7.5 AstraZeneca Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Oncology Drugs Business (2021-2026)
- 12.8.4 Pfizer Oncology Drugs Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Amgen
- 12.9.1 Amgen Company Information
- 12.9.2 Amgen Business Overview
- 12.9.3 Amgen Revenue in Oncology Drugs Business (2021-2026)
- 12.9.4 Amgen Oncology Drugs Product Portfolio
- 12.9.5 Amgen Recent Developments
- 12.10 Eli Lilly
- 12.10.1 Eli Lilly Company Information
- 12.10.2 Eli Lilly Business Overview
- 12.10.3 Eli Lilly Revenue in Oncology Drugs Business (2021-2026)
- 12.10.4 Eli Lilly Oncology Drugs Product Portfolio
- 12.10.5 Eli Lilly Recent Developments
- 12.11 AbbVie
- 12.11.1 AbbVie Company Information
- 12.11.2 AbbVie Business Overview
- 12.11.3 AbbVie Revenue in Oncology Drugs Business (2021-2026)
- 12.11.4 AbbVie Oncology Drugs Product Portfolio
- 12.11.5 AbbVie Recent Developments
- 12.12 Takeda
- 12.12.1 Takeda Company Information
- 12.12.2 Takeda Business Overview
- 12.12.3 Takeda Revenue in Oncology Drugs Business (2021-2026)
- 12.12.4 Takeda Oncology Drugs Product Portfolio
- 12.12.5 Takeda Recent Developments
- 12.13 Astellas
- 12.13.1 Astellas Company Information
- 12.13.2 Astellas Business Overview
- 12.13.3 Astellas Revenue in Oncology Drugs Business (2021-2026)
- 12.13.4 Astellas Oncology Drugs Product Portfolio
- 12.13.5 Astellas Recent Developments
- 12.14 Ipsen
- 12.14.1 Ipsen Company Information
- 12.14.2 Ipsen Business Overview
- 12.14.3 Ipsen Revenue in Oncology Drugs Business (2021-2026)
- 12.14.4 Ipsen Oncology Drugs Product Portfolio
- 12.14.5 Ipsen Recent Developments
- 12.15 Sanofi
- 12.15.1 Sanofi Company Information
- 12.15.2 Sanofi Business Overview
- 12.15.3 Sanofi Revenue in Oncology Drugs Business (2021-2026)
- 12.15.4 Sanofi Oncology Drugs Product Portfolio
- 12.15.5 Sanofi Recent Developments
- 12.16 Bayer
- 12.16.1 Bayer Company Information
- 12.16.2 Bayer Business Overview
- 12.16.3 Bayer Revenue in Oncology Drugs Business (2021-2026)
- 12.16.4 Bayer Oncology Drugs Product Portfolio
- 12.16.5 Bayer Recent Developments
- 12.17 Biogen Idec
- 12.17.1 Biogen Idec Company Information
- 12.17.2 Biogen Idec Business Overview
- 12.17.3 Biogen Idec Revenue in Oncology Drugs Business (2021-2026)
- 12.17.4 Biogen Idec Oncology Drugs Product Portfolio
- 12.17.5 Biogen Idec Recent Developments
- 12.18 Teva
- 12.18.1 Teva Company Information
- 12.18.2 Teva Business Overview
- 12.18.3 Teva Revenue in Oncology Drugs Business (2021-2026)
- 12.18.4 Teva Oncology Drugs Product Portfolio
- 12.18.5 Teva Recent Developments
- 12.19 Otsuka
- 12.19.1 Otsuka Company Information
- 12.19.2 Otsuka Business Overview
- 12.19.3 Otsuka Revenue in Oncology Drugs Business (2021-2026)
- 12.19.4 Otsuka Oncology Drugs Product Portfolio
- 12.19.5 Otsuka Recent Developments
- 12.20 Eisai
- 12.20.1 Eisai Company Information
- 12.20.2 Eisai Business Overview
- 12.20.3 Eisai Revenue in Oncology Drugs Business (2021-2026)
- 12.20.4 Eisai Oncology Drugs Product Portfolio
- 12.20.5 Eisai Recent Developments
- 12.21 Merck KGaA
- 12.21.1 Merck KGaA Company Information
- 12.21.2 Merck KGaA Business Overview
- 12.21.3 Merck KGaA Revenue in Oncology Drugs Business (2021-2026)
- 12.21.4 Merck KGaA Oncology Drugs Product Portfolio
- 12.21.5 Merck KGaA Recent Developments
- 12.22 Gilead Sciences
- 12.22.1 Gilead Sciences Company Information
- 12.22.2 Gilead Sciences Business Overview
- 12.22.3 Gilead Sciences Revenue in Oncology Drugs Business (2021-2026)
- 12.22.4 Gilead Sciences Oncology Drugs Product Portfolio
- 12.22.5 Gilead Sciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst